Natural Capsules Limited · NSE:NATCAPSUQ
Natural Capsules — Investor Presentation (May 2024)
30 slides from Natural Capsules's investor presentation, May 2024
Slide 1: Investor Presentation May 2024
naturalcapsules.com Investor BSE: 524654 Presentation M AY, 2 0 2 4
Slide 2: Safe Harbor
Safe Harbor INVESTOR PRESENTATION Certain statements and opinions with respect to the anticipated future performance of Natural Capsules Limited (NCL) in the presentation (“forward - looking statements”), which reflect various assumptions concerning the strategies, objectives and anticipated results
Slide 3: Inside this document
Inside this document INVESTOR PRESENTATION Q U A R T E R LY C O M PA N Y BUSINESS HIGHLIGHTS OVERVIEW C A NVA S NATURAL CAPSULES LIMITED FINANCIAL INVESTMENT PERFORMANCE MERITS | 3
Slide 4: Quarterly Highlights
naturalcapsules.com Quarterly Highlights
Slide 5: Quarterly Updates – Q4FY24 (Consolidated)
Quarterly Updates – Q4FY24 (Consolidated) INVESTOR PRESENTATION REVENUES 40.22 cr EBITDA 4.11 cr 0.60% Q-o-Q -12.92% Q-o-Q 6.91% Y-o-Y -38.10% Y-o-Y EBITDA MARGINS 10.22% PAT 0.97 cr -159 BPS Q-o-Q -19.83% Q-o-Q -743 BPS Y-o-Y -63.53% Y-o-Y NATURAL CAPSULES LIMITED EPS ₹ 1.31 1.55% Q-o-Q -53.21% Y-o
Slide 6: Management Commentary
Management Commentary INVESTOR PRESENTATION I am pleased to report on our performance the FY24. This year presented numerous challenges, including a difficult operating environment and delays in executing our capital expenditure plans. In the capsules segment, we experienced a decline in topline rev
Slide 7: Profit & Loss Statement Summary (Consolidated)
Profit & Loss Statement Summary (Consolidated) INVESTOR PRESENTATION PARTICULARS (₹ IN CRORES) Q4FY23 Q3FY24 Q4FY24 Q-o-Q Y-o-Y FY23 FY24 Y-o-Y Revenue From Operations 37.62 39.98 40.22 0.60% 6.91% 172.37 155.42 -9.83% Other Income 0.21 0.50 0.92 84.00% 338.10% 0.57 1.94 240.35% Total Income 37.83 4
Slide 8: Company Overview
naturalcapsules.com Company Overview
Slide 9: Introducing Natural Capsules Limited (NCL)
Introducing Natural Capsules Limited (NCL) INVESTOR PRESENTATION Natural Capsules Limited (NCL) is a hard capsule shell manufacturer, who pioneered manufacturing of vegetarian capsules in India and is the second largest Indian manufacturer for gelatin capsules. The company was incorporated as a Publ
Slide 10: Our Journey
Our Journey INVESTOR PRESENTATION 1993- 2014: EARLY SUCCESSES AND A PERIOD OF EXPANSION 1993-95 2001 2003 2004 2005-07 2009-12 2012-14 • NCL was • Soon after, in • 2003 was an • The coming • In 2005-2007, NCL • In 2009-2012, • In 2012-14, NCL incorporated in 2001, NCL important decade witnessed acqu
Slide 11: Our Journey (contd.)
Our Journey (contd.) INVESTOR PRESENTATION 2015 – 2018: THE HURDLES WE 2019 ONWARD: THE BEGINNING GOING FORWARD FACED ON THE WAY OF A NEW AND IMPROVED NCL 2015 – 18 2019 ONWARD Installed capacity as at Q4FY24 stands at 18.75 BCPA • Fall in oil and commodity prices led to economic • 2019 onward NCL w
Slide 12: Product Offerings
Product Offerings INVESTOR PRESENTATION Natural Capsules Limited manufactures a vast array capsules, including vegetarian capsules which they have pioneered in India. The company is now foraying into API manufacturing with complex CA P S ULES A P Is high-end patented technology developed in-house, u
Slide 13: Global Presence
Global Presence INVESTOR PRESENTATION Natural Capsules exports to 28 countries across 5 continents, bringing in sizable revenue from its export. % OF EXPORT SALES AFRICA CIS • Ghana • Georgia 1.57% • Kenya • Uzbekistan • Nigeria • Turkey • South Africa • Russian Federation CIS • Tunisia • Uganda MID
Slide 14: Serving Leading Brands
Serving Leading Brands INVESTOR PRESENTATION With over 3 decades of CUSTOMERS FOR REPEAT BUSINESS MORE THAN 10 YEARS DURING FY24 experience in the pharma sector, NCL has garnered 24% of total customers 89% of total turnover excellent relationship with customers across 28 countries. CUSTOMERS FOR MOR
Slide 15: Board of Directors
Board of Directors INVESTOR PRESENTATION Mr. Laxminarayan Mundra Mr. Satyanarayana Mundra Mr. Sushil Kumar Mundra Mr. Sunil Mundra WHOLE TIME DIRECTOR WHOLE TIME DIRECTOR DIRECTOR MANAGING DIRECTOR NATURAL CAPSULES LIMITED Mr. Pramod Kasat Mr. C P Rangachar Mr. S G Belapure Mrs. Jyothi Mundra INDEPE
Slide 16: Business Canvas
naturalcapsules.com Business Canvas
Slide 17: Capsules Segment
Capsules Segment INVESTOR PRESENTATION With almost three decades of experience in the industry, Natural Capsules Limited is a leading manufacturer of hard capsules in India, its products are exported to regulated and unregulated markets across the globe, 2nd largest following stringent applicable ru
Slide 18: Enhancing Capacities
Enhancing Capacities INVESTOR PRESENTATION Natural Capsules Limited has undergone recent CAPEX, to support its existing manufacturing capacity and to enable the company to capture market share in regulated markets. CAPSULES MANUFACTURING CAPACITY The ability to deliver faster ₹ 38 Crores of capital
Slide 19: API Segment
API Segment INVESTOR PRESENTATION Natural Capsules Limited is now foraying into the API business segment through its subsidiary - Natural Biogenex Private Limited (NBPL) Greenfield Capex at incorporated in 2020. The APIs that will be manufactured Tumkur, spread across 5 acres are,Hydrocortisone, Pre
Slide 20: API Segment (contd.)
API Segment (contd.) INVESTOR PRESENTATION THE FOLLOWING PRODUCTS AND CAPACITIES HAVE BEEN APPROVED UNDER THE PLI SCHEME DEXAMETHASONE 10 MT 24 MT • NCL will be the only manufacturer of this product Planned Capacity Imports to India in FY24 in India worth ~ ₹106 crores B E TA M E T H A S O N E 12 MT
Slide 21: Production Linked Incentive (PLI) Scheme
Production INVESTOR PRESENTATION Linked Incentive (PLI) Scheme • The scheme intends to boost domestic manufacturing of identified KSMs, Drug Intermediates and APIs by attracting large investments in the sector and thereby reduce India’s import dependence in critical APIs. With a view to attain self-
Slide 22: Focus on R&D
Focus on R&D INVESTOR PRESENTATION NCL strongly believes in investing in R&D, to stay ahead of its peers and to consistently innovate. The Company’s recent entry into the API business is 2 DSIR a testament to its firm belief in R&D. Recognised state of the art R&D facilities R&D SPENDS & KEY AREAS O
Slide 23: Financial Performance
naturalcapsules.com Financial Performance
Slide 24: Profit & Loss Statement Summary (Consolidated)
Profit & Loss Statement Summary (Consolidated) INVESTOR PRESENTATION PARTICULARS (₹ IN CRORES) FY20 FY21 FY22 FY23 FY24 Revenue from Operations 61.55 79.51 135.07 172.37 155.42 Other Income 0.95 0.73 1.01 0.57 1.94 Total Income 62.50 80.24 136.08 172.94 157.36 Total Operating Expenses 56.25 68.58 10
Slide 25: Balance Sheet Summary (Consolidated)
Balance Sheet Summary (Consolidated) INVESTOR PRESENTATION PARTICULARS (₹ IN CRORES) FY20 FY21 FY22 FY23 FY24 Total Equity (Networth) 55.62 62.10 82.98 148.25 228.80 Non-Current Liabilities 1.08 1.55 34.85 73.57 71.25 Current Liabilities 17.98 33.30 46.45 66.89 76.47 Total Equity and Liability 74.68
Slide 26: Cash Flow Statement Summary (Consolidated)
Cash Flow Statement Summary (Consolidated) INVESTOR PRESENTATION PARTICULARS (₹ IN CRORES) FY20 FY21 FY22 FY23 FY24 Cash Flow from Operating Activities 6.90 5.78 1.16 17.22 (8.35) Cash Flow from Investing Activities (5.74) (8.54) (45.88) (104.63) (72.59) Cash Flow from Financing Activities (1.18) 2.
Slide 27: Investment Merits
naturalcapsules.com Investment Merits
Slide 28: Growth Drivers
Growth Drivers INVESTOR PRESENTATION Capacity enhancement with Being the only backward Exploring opportunities The Company will benefit state-of-the-art machinery integrated manufacturer to set up capsules from strong industry tailwinds in capsules division, enabling of steroidal APIs in India, manu
Slide 29: Strategic Priorities
Strategic Priorities INVESTOR PRESENTATION NCL is geared to bring about monumental changes in its approach towards its business. With the ongoing CAPEX, the S T R AT E G I C P R I O R I T Y A C T I O N S TA K E N Company is enabling itself to • Positioning the business to reduce margin • Collaborati
Slide 30: Thank You
naturalcapsules.com Thank You CONTACT US FOR FURTHER INFORMATION, PLEASE CONTACT Natural Capsules Limited Mrs. Shilpa Burman Mr. Abhishek Mehra TRIDENT TOWERS, COMPANY SECRETARY INVESTOR RELATIONS ADVISOR Fourth Floor, No. 23, +91 95588 14500 100 Feet Road, Jaynagar II Block, Bangalore - 560 011, IN